Examining the Therapeutic Advances in Fabry Disease Treatment Landscape
What is Fabry Disease?
Fabry Disease is caused due to the excessive buildup of a particular type of fat in the body cells called Globotriaosylceramide. Fabry Disease is usually an inherited disease, and the symptoms of Fabry Disease at an early age can affect the body parts. Fabry disease is a rare but fatal disease. The person affected by Fabry Disease is affected by don’t have enzymes to break down lipids or fat in the body. The fat then gets collected in the blood vessels and tissues, which can result in the risk of heart attack, stroke, and kidney failure. This inherited disease is passed from parents to the child and so on.
Fabry disease is a rare but fatal disease. The lipid storage in the body can result in life-threatening episodes. Males are more prone to inherit Fabry Disease than females. According to research, it was estimated that the life expectancy of the person affected by Fabry Disease is about 58 years. The symptoms of Fabry Disease include pain that spreads throughout the body known as Fabry Crisis, Gastrointestinal complications, Headaches, hearing impairment, Impaired sweating, and vertigo.
Fabry Diseases Epidemiology
Till now we have discussed what is a Fabry disease? What are the signs and symptoms of Fabry Disease? Now we will discuss the epidemiology of the Fabry disease. As per DelveInsight analysis, it was estimated that Fabry Disease prevalence in the 7MM was estimated to be approximately 13K cases in the year 2020., with theUnited States accounting for the maximum number of cases. As per our estimates, males are more prone to Fabry disease as compared to females in the United States. Fabry Disease epidemiology segmentation can be done based on the prevalent cases of Fabry Disease, Phenotype-specific cases of Fabry Disease, Gender-specific cases of Fabry Disease, and Age-specific cases of Fabry Disease.
Fabry Diseases Market Insights
In recent years, there are many factors that have been anticipated to fuel the Fabry Disease market in the upcoming years. Factors such as increasing Disease prevalence, currently marketed therapies, pipeline therapies with a new mechanism of action, and the expected launch of new potential therapies in the market will boost the Fabry Disease Market Size.
According to the DelevInsight, the Fabry Disease market size was valued at USD 1,195.3 million in the year 2020.
Fabry Disease Key Companies
Many key pharmaceutical companies are involved in the development of Fabry Disease Drugs in the upcoming years. The key companies such as - Protalix Biotherapeutics, Sanofi Genzyme, Idorsia Pharmaceuticals, Avrobio, Sangamo Therapeutics, Shire, Takeda, Amicus Therapeutics, Ozmosis Research Inc, CellGenTech, Inc, uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Sigilon Therapeutics, 4D Molecular Therapeutics, and Freeline Therapeutics, are currently developing new Fabry Disease treatment therapies that are expected to be launch in the upcoming years which will serve as a major booster for Fabry Disease treatment market.
Way Ahead
The current Fabry Disease market is lacking many therapies apart from those working on the Enzymes Replacement Therapies. Enzymes Replacement Therapies (ERT) have delivered a potential outcome in the treatment of the Fabry Disease population. However, the Enzymes Therapy must be delivered continuously, which is a challenging part of the ERT as it requires repeated calculations. Despite the fact that ERT is tolerated well by the population, there are still improvements to be done.
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Comments
Post a Comment